TMED4 Inhibitors
Chemical inhibitors of TMED4 play a crucial role in modulating the function of this protein, which is integral to the vesicular trafficking pathways within cellular compartments. Brefeldin A, for example, disrupts the secretory pathway by inhibiting vesicular transport from the endoplasmic reticulum to the Golgi apparatus, thereby impeding TMED4's role in this process. Similarly, Golgicide A targets GBF1, a factor essential for Golgi structure and function, thus affecting the vesicular fusion and transport functions of TMED4. Another inhibitor, Exo1, disrupts the function of the exocyst complex, which is vital for vesicle tethering during exocytosis, leading to an inhibition of the vesicle transport processes involving TMED4. Dynasore, by inhibiting dynamin, hinders the scission of clathrin-coated vesicles, a step necessary for TMED4-mediated vesicle release.
Continuing the exploration of TMED4 inhibition, Monensin alters the pH within the Golgi apparatus, thereby disturbing the protein secretion process that TMED4 facilitates. Tunicamycin inhibits N-linked glycosylation, resulting in improperly glycosylated proteins that TMED4 is supposed to traffic, leading to dysfunctional vesicular transport. Swainsonine and Castanospermine, by inhibiting mannosidase II and glucosidases respectively, affect the processing of N-linked glycans, critical for the maturation of glycoproteins that TMED4 transports. Ilomastat's inhibition of MMPs can affect the extracellular matrix remodeling, impacting the vesicle trafficking mediated by TMED4. Finally, Nocodazole disrupts microtubule polymerization, essential for vesicle transport along microtubules, thus directly affecting the capability of TMED4 to facilitate vesicular trafficking.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits the vesicular transport from the endoplasmic reticulum to the Golgi apparatus. As TMED4 is involved in the trafficking between these organelles, Brefeldin A would inhibit TMED4’s function by disrupting the protein transport and secretion pathway it is involved in. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically targets the Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), which is essential for maintaining Golgi structure and function. As TMED4 is part of the vesicular trafficking process, inhibiting GBF1 would disrupt TMED4's ability to mediate vesicle fusion and transport. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 inhibits exocyst complex function, which is important for vesicle tethering during exocytosis. Since TMED4 is involved in the secretion pathway, the inhibition of the exocyst complex would disrupt the vesicle transport processes that TMED4 facilitates. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a GTPase involved in the scission of clathrin-coated vesicles from the membrane. TMED4, being involved in vesicular trafficking, relies on the proper formation and release of these vesicles; thus, Dynasore would inhibit the function of TMED4 by hindering vesicle release. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin disrupts Golgi function by altering the pH and inhibiting the secretion of proteins. Since TMED4 is implicated in protein trafficking and secretion, Monensin would inhibit TMED4 function by disturbing the Golgi apparatus's pH gradient, which is crucial for TMED4's role in vesicle formation and secretion. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation by inhibiting the enzyme dolichyl-phosphate N-acetylglucosaminephosphotransferase. TMED4, which is involved in protein folding and trafficking, would be inhibited by Tunicamycin due to improper glycosylation of the proteins it traffics, leading to dysfunctional vesicular transport. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme involved in processing N-linked glycans during glycoprotein maturation. By impeding this process, Swainsonine would inhibit TMED4 function by leading to misprocessing of glycoproteins that TMED4 is involved in transporting, thus affecting the protein transport pathway. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits glucosidases, which are enzymes involved in the trimming of N-linked glycans in the ER. TMED4's role in glycoprotein trafficking implies that inhibition of proper glycan processing by Castanospermine would disrupt the proteins' maturation and trafficking that TMED4 mediates. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
Ilomastat inhibits matrix metalloproteinases (MMPs), which play a role in extracellular matrix remodeling and may be involved in vesicle fusion. As TMED4 is part of vesicle-mediated processes, the inhibition of MMPs can impair the extracellular environment required for TMED4-mediated vesicle trafficking. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is essential for vesicle transport along microtubules. TMED4's role in vesicular trafficking would be inhibited by Nocodazole as it would prevent the transport of vesicles along microtubules,It seems you've requested a list of chemicals and their potential effects on TMED4, a protein involved in vesicular trafficking. | ||||||